Status:
COMPLETED
EndoTic - Endothelium and Ticagrelor
Lead Sponsor:
Fundación Investigación Sanitaria en León
Collaborating Sponsors:
AstraZeneca
Conditions:
Acute Coronary Syndrome (ACS)
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Randomized clinical trial to assess the influence of treatment with ticagrelor or clopidogrel in the number of CECs (Circulating Endothelial Cells) and EPCs (Endothelial Progenitor Cells) in patients ...
Detailed Description
ACS Patients in both treatment groups will be assessed: Baseline, 48h and 1 month cell counts will be done for CECs and EPCs Platelet Function at 48h and 1month Adverse Events, ECG and blood testing ...
Eligibility Criteria
Inclusion
- Willing to sign Informed Consent Form
- 18 yr or older
- Male and female (post menopause or contraception treatment)
- ACS diagnosed with elevation of myocardial infarction biomarkers (as of 3rd Universal Definition of MI)
- Planned invasive strategy (coronariography performed within 72hrs after admission)
Exclusion
- Aspirin, clopidogrel or ticagrelor allergy.
- Hemorrhagic diathesis or very high risk of bleeding.
- Current treatment with oral anticoagulants, thienopyridines or ticagrelor.
- Limited life expectancy.
- Elective surgery planned.
- High chance of not being able to complete the follow-up period.
Key Trial Info
Start Date :
March 1 2015
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2016
Estimated Enrollment :
109 Patients enrolled
Trial Details
Trial ID
NCT02244710
Start Date
March 1 2015
End Date
September 1 2016
Last Update
November 23 2016
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Hospital Universitario de Santiago
Santiago de Compostela, La Coruña, Spain
2
Hospital de Leon
León, Leon, Spain, 24008
3
Hospital Universitario de Salamanca
Salamanca, Spain